Benchmark testing shows evidence preparation dropping from up to 6 hours to as little as 5 minutes, with manual review shrinking from days or weeks to hours.

PORTLAND, Ore. and COIMBATORE, India, July 17, 2026 /PRNewswire/ — Exterro today introduced ARMOURop, a new on-premises AI solution that enables digital forensic labs to use AI without sending sensitive case evidence to a public cloud service. Unlike general-purpose AI tools that summarize information or generate responses, ARMOURop combines AI reasoning with governed forensic execution. AI interprets the investigative objective and coordinates supported forensic workflows, while Exterro’s proprietary forensic technology performs the authorized work against locally loaded evidence. Sensitive evidence remains within the agency’s controlled environment throughout the investigation.

The result is faster, more scalable forensic work while designed to preserve chain of custody, evidentiary integrity, and examiner accountability. Representative benchmark testing demonstrates the impact: preparing a one-terabyte evidence set can be reduced from four to six hours to as little as one to five minutes, while CSAM grading that previously consumed a full week can be completed in one to three hours, enabling investigators to reach examiner-validated findings significantly faster.

Results reflect representative benchmark workloads and may vary based on hardware, evidence composition, configuration, data volume, and investigative workflow.

“The first generation of AI helped professionals search faster and summarize more information. Digital forensics demands something far more rigorous. Every finding must be supported by evidence, validated by an examiner, and capable of withstanding legal scrutiny. ARMOURop connects AI reasoning directly to Exterro’s proprietary forensic technology, enabling AI to coordinate supported forensic workflows while experienced investigators remain responsible for every finding, decision, and conclusion,” said Harsh Behl, VP of DFIR Product Management at Exterro.

Built for the Digital Evidence Backlog Overwhelming Forensic Labs

Digital evidence is expanding faster than forensic examiners can examine it. Around 85% of criminal investigations now rely on electronic evidence, and requests for data from service providers have tripled since 2017. The FBI notes that a single modern phone can hold up to half a terabyte of data. The backlog is not theoretical. In 2025, Indiana State Police’s 15-person Digital Forensic Unit examined 1,769 devices and still ended the year with 639 pending; South Wales Police reported 722 devices awaiting examination, with nearly 300 already waiting three to six months. Forensic examiners spend too much of their day on repetitive first-pass reviews rather than on interpretation, validation, reporting, and complex case decisions.

ARMOURop changes the starting point entirely. Instead of manually selecting, sequencing, and operating forensic functions across every evidence source, forensic examiners describe what the investigation must establish. ARMOURop interprets the objective, coordinates the supported forensic workflow, and Exterro’s technology performs the work — media analysis, known-hash comparison, transcription, facial detection, communications review, artifact analysis, and evidence correlation — returning organized findings for examiner review and validation.

The examiner remains in control throughout: defining scope, reviewing evidence, excluding false leads, validating findings, and determining what the evidence supports before any conclusion is used in the case.

The impact across the digital investigations that matter most:

CSAM and ICAC investigations – Hash matching, image classification, and known-content comparison across 10,000 images is reduced from a full week to one to three hours, reducing both case backlog and examiner exposure time to harmful content.Homicide and criminal investigations – Facial detection across 10,000 images drops from three days to one hour; image and video classification drops from three days to six to eight hours, giving detectives investigative direction while evidence remains actionable.Evidence processing at scale – A one-terabyte evidence set prepared for investigation in one to five minutes instead of four to six hours, with a broad range of forensic artifact types—including mobile, communications, memory, drone, and application data—unified in a single console.

“The challenge facing digital forensics today isn’t simply processing more evidence; it’s helping experienced forensic examiners accomplish dramatically more with the time they have. AI shouldn’t simply make individual forensic tasks faster; it should help forensic laboratories complete more investigations by coordinating supported forensic work while keeping every investigative decision under examiner control. That is exactly what ARMOURop delivers,” said Ajith Samuel, Chief Product Officer at Exterro.

Advancing Exterro’s Vision for Governed AI

ARMOURop advances Exterro’s ARMOUR (Autonomous Risk Management, Orchestration, and Unified Response) framework, the company’s architecture for moving organizations beyond question-answering AI to governed, auditable, and defensible AI-coordinated execution through Exterro technology, with investigators in control where expertise and judgment are required. For digital forensic laboratories, that means investigating more cases, reducing growing evidence backlogs, and delivering examiner-validated findings faster, while keeping sensitive evidence under agency control and investigators at the center of every consequential decision. To learn more about Exterro’s AI strategy and the ARMOUR framework, visit www.exterro.com/armour.

Availability

ARMOURop is now available, with a 14-day trial offered upon request. To learn more, visit www.exterro.com.

(Sources: Council of Europe / UNODC, Electronic Evidence Report; FBI Digital Evidence Documentation; Indiana State Police 2025 Annual Report; South Wales Police disclosure)

About Exterro

Exterro empowers organizations to manage data risks with a complete platform for e-discovery, data privacy, cybersecurity and governance, and digital forensics. Unlike any other software provider, Exterro makes it easy for organizations to understand their data and take swift action. Exterro’s AI-driven solutions provide accurate, actionable insights, enabling businesses to support compliance efforts, reduce risks, and streamline operations while lowering costs. With Exterro, organizations gain the clarity and confidence needed to address their most critical data challenges.

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/exterros-armourop-delivers-a-force-multiplier-for-digital-forensic-labs-slashing-evidence-review-time-by-up-to-95-302826202.html

BEIJING, July 16, 2026 /PRNewswire/ — Where can you experience Beijing’s performing arts scene in just one day? More places than you might expect. From immersive dining experiences and century-old opera to rooftop concerts and riverside performances, discover how Beijing transforms everyday places into unforgettable stages. Here, culture isn’t something you simply watch—it’s something you step into.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cctv-hello-beijing-a-city-alive-with-performing-arts-302828241.html

SOURCE CCTV+

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnticipated topline efficacy and safety results for NUZ-001 now expected in late Q2 CY2027Completion of recruitment materially de-risks execution of Neurizon’s lead late-stage clinical programReflects strong recruitment and effective execution across the HEALEY ALS Platform Trial networkParticipants now progressing through the planned 36-week randomised treatment period

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ — Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late-stage clinical biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that enrolment has been completed in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating the Company’s lead investigational therapy NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS).

Neurizon advises that the final participant has completed their baseline visit and commenced treatment, completing enrolment into Regimen I. Reflecting the rapid pace of recruitment, the Company now expects to report topline efficacy and safety results in late Q2 CY2027, earlier than previously anticipated.

Completion of enrolment, together with the earlier anticipated timing of the topline results readout, further demonstrates the continued advancement of the late-stage clinical development program for NUZ-001 for the treatment of ALS. Regimen I completed enrolment in less than five months from first participant dosing, becoming the fastest regimen to activate sites and complete enrolment in the HEALEY ALS Platform Trial, even after the planned sample size expansion from 160 to 240 participants in response to strong recruitment momentum.

This achievement reflects the strength of recruitment across the HEALEY ALS Platform Trial network, one of the world’s leading ALS clinical trial initiatives, the operational efficiencies introduced under the trial’s next generation master protocol, and the commitment of investigators, research coordinators and clinical site teams across the United States. 

Neurizon sincerely acknowledges every person living with ALS and their families who has chosen to participate in this research, recognising that their commitment is fundamental to advancing clinical research and the development of potential new treatment options for the ALS community.

Participants will now continue through the 36-week Randomised Controlled Trial phase before entering the 36-week Active Treatment Extension phase, with the Company’s focus centred on continued execution ahead of the anticipated topline readout in late Q2 CY2027.

Interim Executive Chairman, Mr Sergio Duchini said: “Completion of enrolment represents a major milestone in the clinical development of NUZ-001. Importantly, the rapid completion of recruitment has enabled the anticipated timing of topline efficacy and safety results to be accelerated into late Q2 CY2027, bringing forward an important value inflection point for Neurizon and our shareholders.

On behalf of the Company, I would like to sincerely thank every person living with ALS and their families who chose to participate in this trial. Their willingness to contribute to research despite the immense challenges of this disease is inspiring and is fundamental to advancing the development of new treatment options for people living with ALS.

I would also like to acknowledge the outstanding work of the HEALEY ALS Platform Trial team, investigators, research coordinators and clinical site teams whose expertise, collaboration and commitment have made this achievement possible.

With recruitment now complete, our focus turns to delivering the study with the same operational discipline that has characterised the program to date. We look forward to advancing NUZ-001 through clinical development and towards the anticipated topline efficacy and safety results.”

Director of the Sean M. Healey & AMG Center and Executive Director of the Mass General Brigham Neuroscience Institute, Merit Cudkowicz, MD, MSc said: “We are grateful to everyone who helped complete enrolment in Regimen I in such a short amount of time. We believe strongly in importance of speed, efficiency and high quality in clinical trials. Our patients tell us that the ALS clock is faster and we need to work collaboratively to develop treatments sooner. This is one of the guiding principles of the Healey ALS Platform Trial, Next Generation. The rapid speed of enrolment in this regimen is a testament to the hard work of participants and their families and study staff across all the participating NEALS sites, as well as to the optimised Platform Trial infrastructure.”

About the HEALEY ALS Platform Trial:

The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in the United States (US), created in partnership with the Network of Excellence for ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug candidates reviewed and selected by expert committees based on scientific merit and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial is to accelerate the development of potential new ALS therapies.

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late-stage clinical biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.
To access Neurizon Investor Hub please visit https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited.

View original content:https://www.prnewswire.com/news-releases/healey-als-platform-trial-regimen-i-enrolment-completed–topline-results-for-nuz-001-accelerated-to-q2-cy2027-302828248.html

SOURCE Neurizon Therapeutics Limited